These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 6616602)

  • 1. Clinical pharmacological aspects of dihydroergotamine timed release: activity on monoamine venospasm.
    Franchi G; Anselmi B; Del Bianco PL; Panconesi A; Sicuteri F
    Cephalalgia; 1983 Aug; 3 Suppl 1():185-8. PubMed ID: 6616602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ergot derivatives in the prophylaxis of migraine: a multicentric study with a timed-release dihydroergotamine formulation.
    Martucci N; Manna V; Mattesi P; Troiani G; Manzoni GC; Lanfranchi M; Bono G; Micieli G
    Cephalalgia; 1983 Aug; 3 Suppl 1():151-5. PubMed ID: 6352046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experimental pharmacological studies of the venous tonus-modifying effect of dihydroergotamine].
    Glusa E
    Z Gesamte Inn Med; 1984 Sep; 39(17):414-7. PubMed ID: 6095548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy.
    Schaerlinger B; Hickel P; Etienne N; Guesnier L; Maroteaux L
    Br J Pharmacol; 2003 Sep; 140(2):277-84. PubMed ID: 12970106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects on arterial receptors of ergot derivatives used in migraine.
    Müller-Schweinitzer E; Fanchamps A
    Adv Neurol; 1982; 33():343-56. PubMed ID: 6275676
    [No Abstract]   [Full Text] [Related]  

  • 6. On the treatment of migraine. Pharmacokinetic-pharmacodynamic relationships for a programmed release formulation of dihydroergotamine administered orally in the human.
    Aylward M; Davies DE; Maddock J; Robinson PR; Jones M
    Cephalalgia; 1983 Aug; 3 Suppl 1():146-50. PubMed ID: 6616596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacology of ergotamine and dihydroergotamine.
    Silberstein SD
    Headache; 1997; 37 Suppl 1():S15-25. PubMed ID: 9009470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ergot pharmacology and alternative delivery systems for ergotamine derivatives.
    Goldstein J
    Neurology; 1992 Mar; 42(3 Suppl 2):45-6. PubMed ID: 1557192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex vivo studies after oral treatment of the beagle with dihydroergotamine.
    Müller-Schweinitzer E; Rosenthaler J
    Eur J Pharmacol; 1983 Apr; 89(1-2):1-8. PubMed ID: 6861880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of morning migraine. Clinical and biokinetic correlation of programmed-release dihydroergotamine].
    Aylward M; Chazot G; Maddock J; Schott B
    Presse Med; 1984 Jun; 13(26):1617-9. PubMed ID: 6234558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Menstrual migraine: intermittent prophylaxis with a timed-release pharmacological formulation of dihydroergotamine.
    D'Alessandro R; Gamberini G; Lozito A; Sacquegna T
    Cephalalgia; 1983 Aug; 3 Suppl 1():156-8. PubMed ID: 6616598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydroergotamine: pharmacokinetics, pharmacodynamics, and mechanism of venoconstrictor action in beagle dogs.
    Müller-Schweinitzer E; Rosenthaler J
    J Cardiovasc Pharmacol; 1987 Jun; 9(6):686-93. PubMed ID: 2442535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DHE retard for prophylactic therapy of migraine: efficacy and tolerability.
    Centonze V; Attolini E; Santoiemma L; Brucoli C; Macinagrossa G; Campanozzi F; Albano O
    Cephalalgia; 1983 Aug; 3 Suppl 1():179-84. PubMed ID: 6616601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relatively slow and long-lasting antimigraine effect of dihydroergotamine is most likely due to basic pharmacological attributes of the drug: a review.
    Tfelt-Hansen PC
    Cephalalgia; 2013 Oct; 33(13):1122-31. PubMed ID: 23588793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine.
    Buzzi MG; Moskowitz MA
    Cephalalgia; 1991 Sep; 11(4):165-8. PubMed ID: 1660351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoamine sensitivity of smooth muscle in vivo in nociception disorders.
    Del Bianco PL; Franchi G; Anselmi B; Sicuteri F
    Adv Neurol; 1982; 33():391-8. PubMed ID: 6275678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dihydroergotamine and its metabolite, 8'-hydroxy-dihydroergotamine, as 5-HT1A receptor agonists in the rat brain.
    Hanoun N; Saurini F; Lanfumey L; Hamon M; Bourgoin S
    Br J Pharmacol; 2003 May; 139(2):424-34. PubMed ID: 12770948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The long term use of dihydroergotamine (DHE-45) in migraine treatment (author's transl)].
    Miyazaki T
    Masui; 1978 Jan; 27(1):79-84. PubMed ID: 633616
    [No Abstract]   [Full Text] [Related]  

  • 19. Venospastic activity of somatostatin in vivo in man: naloxone reversible tachyphylaxis.
    Sicuteri F; Panconesi A; Del Bianco PL; Franchi G; Anselmi B
    Int J Clin Pharmacol Res; 1984; 4(3):253-7. PubMed ID: 6149197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orally inhaled dihydroergotamine: a review.
    Tepper SJ
    Headache; 2013 Sep; 53 Suppl 2():43-53. PubMed ID: 24024602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.